Oddo BHF maintains its 'neutral' rating on Carmat shares, with a price target lowered from €17 to €9.

The capital increase launched a few days ago raised a gross amount of 16.5 ME, corresponding to a net amount of 14.9 ME.

The funds raised will be used to strengthen the company's short-term cash position, in order to support its commercial activities and its clinical trial (EFICAS) in France.

Oddo BHF believes that "a new financing operation is still to be expected in the near future, which could weigh on the share price in the coming months", and points out that the company's objective this year is to achieve sales guidance of between €14 and €20 million, and also to strengthen its cash position in H1.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.